What Are Lysins?

Lysins are enzymes derived from naturally occurring bacteriophage, viruses which infect bacteria. When produced in recombinant form and applied to bacteria, lysins cleave a key component in the structure of the bacterial peptidoglycan cell wall which results in rapid killing of the target bacteria.

What Makes Lysins Different?

Lysins are fundamentally different from conventional antibiotics which require cell division or metabolism in order to kill bacteria or stop their growth. Lysins directly bind and cleave the bacterial cell wall and kill on contact. Lysins therefore have a number of key features that differentiate them from conventional antibiotics:

Key Features

  • Rapid killing of bacteria
  • Ability to clear biofilms
  • Low propensity to develop resistance
  • Full activity against antibiotic-resistant bacteria (while sparing "good" bacteria)
  • Synergy with existing antibiotics

Key Potential

  • Treat MRSA and other drug resistant strains
  • Reduce treatment times
  • Shorten hospital stays
  • Improve patient outcomes

All while not contributing to the global crisis of drug resistance

Lysin Discovery Platform

We have acquired worldwide exclusive rights to nine lysins discovered by Dr. Vincent Fischetti at The Rockefeller University. Each lysin targets specific gram-positive bacteria, including Staph aureus, pneumococcus, group B streptococcus, enterococcus and anthrax.

In addition, our in-house lysin discovery platform consists of bio-informatic and metagenomic-based functional screening of genomic material recovered directly from the environment for large scale identification of lysins to both gram-positive and gram-negative bacteria, enabling the production of lysin banks specific for a particular bacterial pathogen. The ability to rapidly identify new lysins provides a steady pipeline of novel lysins for evaluation as potential antimicrobial therapeutic candidates, including potentially targeting gram negative organisms.

Attributes

Lysin Mechanism of Action

Lysins are a new class of agents for the treatment of bacterial infections. Lysins are recombinant enzymatic proteins derived from bacteriophage that directly digest the cell wall of bacteria leading to rapid bacterial killing. Conventional antibiotics require bacterial cell division and metabolism to occur in order to exert their effect (i.e., cell death or cessation of growth). Lysins, however, are fundamentally different and kill bacteria rapidly upon contact.

Lysins bind and cleave peptidoglycan, which is a crosslinked mesh of proteins and sugars that forms the bacterial cell wall. After binding the peptidoglycan, lysins cleave specific bonds within the peptidoglycan which are required to maintain the structural stability of the cell wall and viability of the bacteria. Importantly, animal cells do not have a peptidoglycan cell wall so this mechanism provides specificity to the bacterial target.

Lysins are enzymes derived from bacteriophage. ContraFect is developing recombinant lysins as a therapeutic which kills bacteria on contact.

Lysin destroying bacteria

Rapid Bactericidal Activity

In vitro experiments indicate that our lead lysin CF-301 can kill Staph aureus 12-18x faster than standard-of-care antibiotics. While conventional antibiotics require bacterial cell division or metabolism to occur in order to exert their effect (i.e., cell death or cessation of growth), lysins act much more directly and quickly. Lysins exert their bactericidal effect on cells immediately by killing on contact through their direct enzymatic activity on bacterial cell walls. Once the cell wall is breached, the bacterium disintegrates rapidly.

Clears Biofilms

Biofilms are densely packed communities of bacteria held together by a slimy matrix. Biofilms act like an armor coating which makes it difficult for conventional antibiotics to reach their target. Bacteria in biofilms may also become dormant, making them further resistant to conventional antibiotics which require bacterial metabolism to exert their effect. As a result, bacteria in biofilms can tolerate as much as 1,000 times more antibiotic than non-biofilm bacteria. Biofilms can be formed by drug-resistant strains of bacteria such as MRSA which makes them even harder to treat. No products today are approved for the treatment of biofilms.

The term “biofilm” was introduced in 1981, and the full extent of their clinical impact is still being understood, though they are thought to be involved in 65-80% of all clinical infections. Biofilms can form on human tissues, such as the heart valve in endocarditis or bone in osteomyelitis, or indwelling medical devices such as central venous catheters, pacemakers, or prosthetic joints. Treatment of biofilm infections can take months of intense antibiotic therapy, and often the only “cure” for a biofilm infection is surgical removal of the material on which it forms, such as the removal of an infected catheter or even the removal of an infected pacemaker, hip or knee prostheses.

Lysins have been shown to be highly effective in clearing biofilms in vitro and in killing the dormant bacteria within the biofilm. Our lysin candidate CF-301 has been shown to clear biofilms in models of catheter biofilm and is highly efficacious in combination with antibiotics in animal models of endocarditis, a serious medical condition that has a significant biofilm component as a key part of its pathology.

Eradicate 1

MRSA biofilm infected catheter

Eradicate 2

CF-301: 30 Seconds: Biofilm eradicated

Eradicate 1

CF-301: 15 Minutes: Catheter sterilized

Favorable Resistance Profile - Narrow Spectrum, Broad Acting

Because of their unique mechanism of action, lysins have many potential advantages related to the treatment of drug resistant strains and in limiting formation of new drug resistance. Drug resistance occurs when bacteria develop mechanisms that impede an antibiotic’s action such as a mutation of the antibiotic binding site or formation of pumps that remove the antibiotic from the inside of the bacteria before it can have an effect. Lysins kill bacteria through enzymatic digestion of highly conserved components of the bacterial cell wall and therefore resistance mechanisms to conventional antibiotics do not impact lysin activity. For example, CF-301 exhibits antimicrobial activity against Staph aureus isolates that are resistant to the antibiotics methicillin (methicillin-resistant Staph aureus; “MRSA”), vancomycin (vancomycin-resistant Staph aureus;”VRSA”), and daptomycin (daptomycin-resistant Staph aureus; “DRSA”).

Lysins are much less susceptible to the formation of drug resistance. Lysins bind and cleave conserved regions of the peptidoglycan shell of bacteria, which is essential to the structural integrity of the bacteria. In serial passage studies of CF-301, it has been shown that bacteria do not form appreciable resistance to its killing effect while other standard of care agents develop resistance under the same conditions.

Unlike standard-of-care antibiotics, which are “broad spectrum” and kill the body’s natural flora (including good bacteria) in addition to the disease-causing bacteria, lysins are “narrow spectrum, broad-acting” anti-infective agents. Due to the specificity of a lysin’s binding domain and catalytic activity, they are highly specific for given species of bacteria (i.e., Staph aureus), making them a narrow spectrum anti-infective. However, lysins are broadly active against the spectrum of strains of the target bacteria, including resistant strains.

The highly targeted activity of lysins may reduce the potential adverse effects that can occur when conventional antibiotic treatments kill the body’s healthy, desirable bacteria.

Synergy with Standard-of-Care Antibiotics

Synergy is defined as the interaction of two or more agents so that their combined effect is greater than the sum of their individual effects. A strong synergistic effect between CF-301 and several standard-of-care antibiotics, including daptomycin, vancomycin and oxacillin, has been demonstrated in preclinical studies.

In order to take advantage of this strong synergistic effect, we intend to conduct clinical trials and eventually seek approval for CF-301 in combination with standard-of-care antibiotics for the treatment of Staph aureus bacteremia. We intend to use of CF-301 in combination with, rather than as a replacement for, standard-of-care antibiotics, which we expect will provide better outcomes for patients.

View

Lysin Candidate: CF-301

CF-301, is a lysin for the treatment of Staph aureus bacteremia.

View CF-301 »
About

Contrafect Corporation

We focus on developing protein and antibody therapeutic products.

Learn More »